Table of contents
Overview of the trial
The available trial record describes an interventional study, which means participants receive a study treatment or a comparison treatment. The study is about adults with Hereditary Hemorrhagic Telangiectasia (HHT) and also includes adult healthy volunteers.[1]
The trial is authorised and has the identification number NCT06659640.[1]
The study title says it is a Phase 1/2 study, but the trial record also lists the phase as Phase 1.[1]
Who can participate
The trial includes adult healthy volunteers and adult patients with HHT.[1]
The source data does not provide more detailed eligibility rules, such as exact age limits, lab cut-offs, or disease severity requirements.[1]
Phase and endpoints
The trial is listed as Phase 1, which usually means early testing in people.[1]
The primary outcome is the frequency of adverse events (AEs), meaning unwanted medical events that happen during the study.[1]
Safety is also checked with vital signs, ECGs (heart rhythm tests), and clinical laboratory assessments.[1]
The brief summary says the study aims to evaluate the safety and tolerability of multiple doses in adult patients with HHT.[1]
Trial summary
This trial is focused on understanding how the study treatment performs in people with HHT and in healthy adults.[1]
It is not presented as a study of long-term disease control in the available record; instead, the main goal is early evaluation of safety-related measures.[1]
Because the source data is limited, the most reliable details are the study phase, target population, trial status, enrollment, and the safety endpoints listed above.[1]
